EMA’s human medicines committee (CHMP) has recommended updating the product information for Comirnaty to clarify that each vial contains 6 doses of the vaccine.

In order to extract six doses from a single vial, low dead-volume syringes and/or needles should be used. The low dead-volume syringe and needle combination should have a dead volume of no more than 35 microliters. If standard syringes and needles are used, there may not be enough of the vaccine to extract a sixth dose from a vial.

If the amount of vaccine remaining in the vial after the fifth dose cannot provide a full dose (0.3 ml), the healthcare professional must discard the vial and its contents. There should be no pooling from multiple vials to make up a full dose, and any unused vaccine should be discarded 6 hours after dilution. Further information on all the steps for using Comirnaty is available in the updated product information.

Comirnaty is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 16 years and older. It was authorised in the EU on 21 December 2020.

Information for healthcare professionals

• After dilution, it is possible to obtain six doses from a vial if you use low dead-volume (≤35 μL) syringes and/or needles for all doses.
• Discard the vial and its contents if the amount of vaccine left in the vial is not enough for a full sixth dose (0.3 ml).
• Do not pool from multiple vials to make up an extra dose.
• Discard any unused vaccine 6 hours after dilution.
• Read the product information for full instructions.

More about the vaccine

Comirnaty is a vaccine for preventing coronavirus disease 2019 (COVID-19) in people aged 16 years and older.

It contains a molecule called messenger RNA (mRNA) with instructions for producing a protein from SARS-CoV-2, the virus that causes COVID-19. The vaccine works by preparing the body to attack the spike protein on the surface of SARS-CoV-2.

For more information see Comirnaty. 

Related content

• Comirnaty: EPAR

Related document

• List itemComirnaty – Product Information as approved by the CHMP on 8 January 2021, pending endorsement by the European Commission (PDF/888.12 KB) (new)
  First published: 08/01/2021

Related content

• Coronavirus disease (COVID-19)
• Treatments and vaccines for COVID-19
• COVID-19 vaccines: key facts
• COVID-19 vaccines: development, evaluation, approval and monitoring
• COVID-19 vaccines: studies for approval
• Transparency: exceptional measures for COVID-19 medicines
• EMA’s governance during COVID-19 pandemic